Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023

Upgrades

For Tabula Rasa HealthCare Inc TRHC, SVB Leerink upgraded the previous rating of Market Perform to Outperform. Tabula Rasa HealthCare earned $0.02 in the first quarter, compared to $0.68 in the year-ago quarter. The current stock performance of Tabula Rasa HealthCare shows a 52-week-high of $6.69 and a 52-week-low of $2.09. Moreover, at the end of the last trading period, the closing price was at $5.52.

According to Maxim Group, the prior rating for Paltalk Inc PALT was changed from Hold to Buy. Paltalk earned $0.08 in the first quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Paltalk shows a 52-week-high of $4.60 and a 52-week-low of $1.28. Moreover, at the end of the last trading period, the closing price was at $2.26.

According to Northland Capital Markets, the prior rating for Vitesse Energy Inc VTS was changed from Market Perform to Outperform. In the first quarter, Vitesse Energy showed an EPS of $0.53, compared to $0.02 from the year-ago quarter. The stock has a 52-week-high of $20.99 and a 52-week-low of $13.90. At the end of the last trading period, Vitesse Energy closed at $18.71.

For Jack In The Box Inc JACK, OTR Global upgraded the previous rating of Mixed to Positive. In the first quarter, Jack In The Box showed an EPS of $2.01, compared to $1.97 from the year-ago quarter. The stock has a 52-week-high of $94.93 and a 52-week-low of $54.86. At the end of the last trading period, Jack In The Box closed at $92.61.

Craig-Hallum upgraded the previous rating for GrowGeneration Corp GRWG from Hold to Buy. GrowGeneration earned $0.10 in the first quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $8.62 and a 52-week-low of $2.77. At the end of the last trading period, GrowGeneration closed at $3.70.

For Corbus Pharmaceuticals Holdings Inc CRBP, Oppenheimer upgraded the previous rating of Perform to Outperform. Corbus Pharmaceuticals earned $4.24 in the first quarter, compared to $2.40 in the year-ago quarter. The stock has a 52-week-high of $13.17 and a 52-week-low of $2.11. At the end of the last trading period, Corbus Pharmaceuticals closed at $8.87.

For Albemarle Corp ALB, Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. In the first quarter, Albemarle showed an EPS of $10.32, compared to $2.38 from the year-ago quarter. At the moment, the stock has a 52-week-high of $334.20 and a 52-week-low of $171.82. Albemarle closed at $195.17 at the end of the last trading period.

B of A Securities upgraded the previous rating for Celsius Holdings Inc CELH from Neutral to Buy. Celsius Holdings earned $0.40 in the first quarter, compared to $0.09 in the year-ago quarter. The current stock performance of Celsius Holdings shows a 52-week-high of $122.24 and a 52-week-low of $38.38. Moreover, at the end of the last trading period, the closing price was at $107.12.

According to B of A Securities, the prior rating for InterDigital Inc IDCC was changed from Underperform to Buy. InterDigital earned $4.21 in the first quarter, compared to $0.58 in the year-ago quarter. The stock has a 52-week-high of $81.95 and a 52-week-low of $40.24. At the end of the last trading period, InterDigital closed at $80.00.

According to Craig-Hallum, the prior rating for Quotient Technology Inc QUOT was changed from Hold to Buy. For the first quarter, Quotient Technology had an EPS of $0.18, compared to year-ago quarter EPS of $0.28. At the moment, the stock has a 52-week-high of $4.56 and a 52-week-low of $1.68. Quotient Technology closed at $2.90 at the end of the last trading period.

Craig-Hallum upgraded the previous rating for Exact Sciences Corp EXAS from Hold to Buy. For the first quarter, Exact Sciences had an EPS of $0.42, compared to year-ago quarter EPS of $1.04. The stock has a 52-week-high of $72.19 and a 52-week-low of $29.29. At the end of the last trading period, Exact Sciences closed at $71.00.

For MasterBrand Inc MBC, Loop Capital upgraded the previous rating of Hold to Buy. For the first quarter, MasterBrand had an EPS of $0.28, compared to year-ago quarter EPS of $0.40. The current stock performance of MasterBrand shows a 52-week-high of $10.21 and a 52-week-low of $7.08. Moreover, at the end of the last trading period, the closing price was at $8.64.

For Y-mAbs Therapeutics Inc YMAB, Wedbush upgraded the previous rating of Neutral to Outperform. For the first quarter, Y-mAbs Therapeutics had an EPS of $0.15, compared to year-ago quarter EPS of $0.64. At the moment, the stock has a 52-week-high of $20.31 and a 52-week-low of $2.70. Y-mAbs Therapeutics closed at $9.23 at the end of the last trading period.

Jefferies upgraded the previous rating for Nektar Therapeutics NKTR from Underperform to Hold. For the first quarter, Nektar Therapeutics had an EPS of $0.25, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $5.17 and a 52-week-low of $0.60. Nektar Therapeutics closed at $0.77 at the end of the last trading period.

Itau BBA upgraded the previous rating for Vtex VTEX from Market Perform to Outperform. In the first quarter, Vtex showed an EPS of $0.04, compared to $0.10 from the year-ago quarter. The stock has a 52-week-high of $5.43 and a 52-week-low of $2.69. At the end of the last trading period, Vtex closed at $3.60.

For Alcon Inc ALC, Baird upgraded the previous rating of Neutral to Outperform. Alcon earned $0.70 in the first quarter, compared to $0.68 in the year-ago quarter. The stock has a 52-week-high of $78.55 and a 52-week-low of $55.21. At the end of the last trading period, Alcon closed at $74.31.

According to Piper Sandler, the prior rating for Halozyme Therapeutics Inc HALO was changed from Neutral to Overweight. For the first quarter, Halozyme Therapeutics had an EPS of $0.47, compared to year-ago quarter EPS of $0.47. The current stock performance of Halozyme Therapeutics shows a 52-week-high of $59.45 and a 52-week-low of $29.85. Moreover, at the end of the last trading period, the closing price was at $30.58.

For The Hain Celestial Group Inc HAIN, Piper Sandler upgraded the previous rating of Underweight to Neutral. For the third quarter, Hain Celestial Group had an EPS of $0.08, compared to year-ago quarter EPS of $0.33. The current stock performance of Hain Celestial Group shows a 52-week-high of $28.13 and a 52-week-low of $15.20. Moreover, at the end of the last trading period, the closing price was at $15.42.

See all analyst ratings upgrades.

Downgrades

According to Alliance Global Partners, the prior rating for Aterian Inc ATER was changed from Buy to Neutral. For the first quarter, Aterian had an EPS of $0.13, compared to year-ago quarter EPS of $0.25. The stock has a 52-week-high of $4.38 and a 52-week-low of $0.67. At the end of the last trading period, Aterian closed at $0.78.

For Innovative Industrial Properties Inc IIPR, Craig-Hallum downgraded the previous rating of Buy to Hold. In the first quarter, Innovative Ind Props showed an EPS of $2.25, compared to $2.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $139.69 and a 52-week-low of $63.36. Innovative Ind Props closed at $71.43 at the end of the last trading period.

Edward Jones downgraded the previous rating for PayPal Holdings Inc PYPL from Buy to Hold. For the first quarter, PayPal Holdings had an EPS of $1.17, compared to year-ago quarter EPS of $0.88. The stock has a 52-week-high of $103.02 and a 52-week-low of $65.85. At the end of the last trading period, PayPal Holdings closed at $65.91.

According to JP Morgan, the prior rating for Dutch Bros Inc BROS was changed from Overweight to Neutral. For the first quarter, Dutch Bros had an EPS of $0.00, compared to year-ago quarter EPS of $0.02. At the moment, the stock has a 52-week-high of $54.13 and a 52-week-low of $20.07. Dutch Bros closed at $32.45 at the end of the last trading period.

For Health Catalyst Inc HCAT, Raymond James downgraded the previous rating of Strong Buy to Market Perform. For the first quarter, Health Catalyst had an EPS of $0.05, compared to year-ago quarter EPS of $0.06. The stock has a 52-week-high of $18.28 and a 52-week-low of $6.41. At the end of the last trading period, Health Catalyst closed at $11.95.

Guggenheim downgraded the previous rating for Health Catalyst Inc HCAT from Buy to Hold. In the first quarter, Health Catalyst showed an EPS of $0.05, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $18.28 and a 52-week-low of $6.41. At the end of the last trading period, Health Catalyst closed at $11.95.

TD Cowen downgraded the previous rating for Dutch Bros Inc BROS from Outperform to Market Perform. Dutch Bros earned $0.00 in the first quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $54.13 and a 52-week-low of $20.07. At the end of the last trading period, Dutch Bros closed at $32.45.

According to Raymond James, the prior rating for Wheels Up Experience Inc UP was changed from Outperform to Market Perform. In the first quarter, Wheels Up Experience showed an EPS of $0.31, compared to $0.25 from the year-ago quarter. The stock has a 52-week-high of $2.88 and a 52-week-low of $0.37. At the end of the last trading period, Wheels Up Experience closed at $0.39.

According to William Blair, the prior rating for Amplitude Inc AMPL was changed from Outperform to Market Perform. Amplitude earned $0.04 in the first quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Amplitude shows a 52-week-high of $19.71 and a 52-week-low of $10.51. Moreover, at the end of the last trading period, the closing price was at $11.63.

According to Jefferies, the prior rating for Prometheus Biosciences Inc RXDX was changed from Buy to Hold. Prometheus Biosciences earned $0.86 in the first quarter, compared to $0.82 in the year-ago quarter. The stock has a 52-week-high of $197.83 and a 52-week-low of $21.57. At the end of the last trading period, Prometheus Biosciences closed at $194.40.

Rosenblatt downgraded the previous rating for Bentley Systems Inc BSY from Buy to Neutral. Bentley Systems earned $0.25 in the first quarter, compared to $0.24 in the year-ago quarter. At the moment, the stock has a 52-week-high of $46.97 and a 52-week-low of $26.33. Bentley Systems closed at $46.31 at the end of the last trading period.

According to Deutsche Bank, the prior rating for AdaptHealth Corp AHCO was changed from Buy to Hold. In the first quarter, AdaptHealth showed an EPS of $0.06, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $27.48 and a 52-week-low of $10.21. At the end of the last trading period, AdaptHealth closed at $11.30.

According to Barclays, the prior rating for Lumentum Holdings Inc LITE was changed from Overweight to Equal-Weight. In the third quarter, Lumentum Holdings showed an EPS of $0.75, compared to $1.19 from the year-ago quarter. The stock has a 52-week-high of $96.45 and a 52-week-low of $44.94. At the end of the last trading period, Lumentum Holdings closed at $45.99.

According to BMO Capital, the prior rating for Expensify Inc EXFY was changed from Outperform to Market Perform. For the first quarter, Expensify had an EPS of $0.05, compared to year-ago quarter EPS of $0.09. The current stock performance of Expensify shows a 52-week-high of $25.36 and a 52-week-low of $7.01. Moreover, at the end of the last trading period, the closing price was at $7.24.

For Southern Copper Corp SCCO, Goldman Sachs downgraded the previous rating of Neutral to Sell. In the fourth quarter, Southern Copper showed an EPS of $1.17, compared to $1.08 from the year-ago quarter. The stock has a 52-week-high of $82.05 and a 52-week-low of $42.49. At the end of the last trading period, Southern Copper closed at $79.04.

BTIG downgraded the previous rating for Wheels Up Experience Inc UP from Buy to Neutral. Wheels Up Experience earned $0.31 in the first quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $2.88 and a 52-week-low of $0.37. At the end of the last trading period, Wheels Up Experience closed at $0.39.

Morgan Stanley downgraded the previous rating for Sealed Air Corp SEE from Overweight to Equal-Weight. For the first quarter, Sealed Air had an EPS of $0.74, compared to year-ago quarter EPS of $1.12. At the moment, the stock has a 52-week-high of $65.96 and a 52-week-low of $41.15. Sealed Air closed at $42.64 at the end of the last trading period.

For Nikola Corp NKLA, TD Cowen downgraded the previous rating of Outperform to Market Perform. Nikola earned $0.26 in the first quarter, compared to $0.21 in the year-ago quarter. The current stock performance of Nikola shows a 52-week-high of $8.97 and a 52-week-low of $0.79. Moreover, at the end of the last trading period, the closing price was at $0.86.

According to Stifel, the prior rating for AdaptHealth Corp AHCO was changed from Buy to Hold. AdaptHealth earned $0.06 in the first quarter, compared to $0.08 in the year-ago quarter. The current stock performance of AdaptHealth shows a 52-week-high of $27.48 and a 52-week-low of $10.21. Moreover, at the end of the last trading period, the closing price was at $11.30.

According to Piper Sandler, the prior rating for Amplitude Inc AMPL was changed from Overweight to Neutral. Amplitude earned $0.04 in the first quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Amplitude shows a 52-week-high of $19.71 and a 52-week-low of $10.51. Moreover, at the end of the last trading period, the closing price was at $11.63.

See all analyst ratings downgrades.

Initiations

Truist Securities initiated coverage on Voyager Therapeutics Inc VYGR with a Buy rating. The price target for Voyager Therapeutics is set to $18.00. In the first quarter, Voyager Therapeutics showed an EPS of $2.94, compared to $0.56 from the year-ago quarter. The current stock performance of Voyager Therapeutics shows a 52-week-high of $11.49 and a 52-week-low of $4.61. Moreover, at the end of the last trading period, the closing price was at $10.76.

With a Equal-Weight rating, Barclays initiated coverage on Pacific Biosciences of California Inc PACB. The price target seems to have been set at $14.00 for Pacific Biosciences. Pacific Biosciences earned $0.31 in the first quarter, compared to $0.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.14 and a 52-week-low of $3.85. Pacific Biosciences closed at $12.03 at the end of the last trading period.

With an Overweight rating, Barclays initiated coverage on 10x Genomics Inc TXG. The price target seems to have been set at $65.00 for 10x Genomics. 10x Genomics earned $0.44 in the first quarter, compared to $0.38 in the year-ago quarter. At the moment, the stock has a 52-week-high of $56.22 and a 52-week-low of $23.85. 10x Genomics closed at $53.23 at the end of the last trading period.

UBS initiated coverage on Hess Midstream LP HESM with a Buy rating. The price target for Hess Midstream is set to $37.00. For the first quarter, Hess Midstream had an EPS of $0.47, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $34.94 and a 52-week-low of $24.34. Hess Midstream closed at $28.42 at the end of the last trading period.

UBS initiated coverage on Antero Midstream Corp AM with a Buy rating. The price target for Antero Midstream is set to $14.00. In the first quarter, Antero Midstream showed an EPS of $0.21, compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.61 and a 52-week-low of $8.57. Antero Midstream closed at $10.47 at the end of the last trading period.

With a Buy rating, DA Davidson initiated coverage on JFrog Ltd FROG. The price target seems to have been set at $25.00 for JFrog. JFrog earned $0.06 in the first quarter, compared to $0.00 in the year-ago quarter. The stock has a 52-week-high of $27.96 and a 52-week-low of $16.42. At the end of the last trading period, JFrog closed at $21.51.

DA Davidson initiated coverage on GitLab Inc GTLB with a Neutral rating. The price target for GitLab is set to $30.00. GitLab earned $0.03 in the fourth quarter, compared to $0.16 in the year-ago quarter. The current stock performance of GitLab shows a 52-week-high of $70.91 and a 52-week-low of $26.24. Moreover, at the end of the last trading period, the closing price was at $31.08.

See all analyst ratings initiations.